TPA-023

TPA-023 is a drug that belongs to the benzodiazepine class of medications. It was developed by a pharmaceutical company called Takeda Pharmaceuticals. TPA-023 is primarily used in the treatment of anxiety and insomnia. It is a partial agonist at GABA_A receptors, which means it can produce similar effects to those of other benzodiazepines, but with less risk of dependency and withdrawal symptoms.

Pharmacology

TPA-023 acts as a partial agonist at [[GABA_A receptors]], which are a type of protein in the brain that responds to the neurotransmitter GABA, the main inhibitory neurotransmitter in the mammalian central nervous system. This action enhances the effect of GABA in the brain, leading to sedative and anxiolytic effects.

Clinical Use

TPA-023 has been studied for use in the treatment of Generalized Anxiety Disorder (GAD) and insomnia. In clinical trials, it has shown efficacy in reducing the symptoms of these conditions, with a lower risk of dependency and withdrawal symptoms compared to other benzodiazepines.

Development and Approval

TPA-023 was developed by Takeda Pharmaceuticals, a Japanese multinational pharmaceutical company. However, development was discontinued in 2007 due to concerns about toxicity in animal studies.

See Also

• Benzodiazepine
• [[GABA_A receptor]]
• Takeda Pharmaceuticals

TPA-023

• 
•